Drug Trial Radar · NCT04626479
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
393
Actual
Start
Dec 16, 2020
Primary completion
Aug 10, 2026
Study completion Aug 10, 2026
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Nov 12, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 120 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Substudy 03A is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03). The goal of substudy 03A is to evaluate the safety and efficacy of experimental combinations of investigational agents in participants with advanced first line (1L) clear cell renal cell carcinoma (ccRCC). This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to demonstrate a tolerable safety profile for the combination of investigational agents. There will be no hypothesis testing in this study.
Conditions
- Carcinoma, Renal Cell
Interventions
PembrolizumabBiological
Administered via IV infusion at a dose of 400 mg Q6W
Favezelimab/PembrolizumabBiological
Administered via IV infusion at a dose of 800 mg/200 mg Q3W
BelzutifanDrug
Administered via oral tablet at a dose of 120 mg QD
LenvatinibDrug
Administered via oral capsule at a dose of 20 mg QD
Pembrolizumab/QuavonlimabBiological
Administered via IV infusion at a dose of 400 mg/25 mg Q6W
Vibostolimab/PembrolizumabDrug
Administered via IV infusion at a dose of 200 mg/200 mg Q6W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety Lead-in Phase: Number of participants who experience one or more dose-limiting toxicities (DLTs)Time frame: Up to ~21 days
- Safety Lead-in Phase: Number of participants who experience one or more adverse events (AEs)Time frame: Up to ~21 days
- Safety Lead-in Phase: Number of participants who discontinue study treatment due to an AETime frame: Up to ~21 days
- Efficacy Phase: Number of participants who experience one or more DLTsTime frame: Up to ~21 days
- Efficacy Phase: Number of participants who experience one or more AEsTime frame: Up to ~43 months
- Efficacy Phase: Number of participants who discontinue study treatment due to an AETime frame: Up to ~43 months
- Efficacy Phase: Objective response rate (ORR)Time frame: Up to ~43 months
Locations
55 sites in 14 countries. Site status is shown where the registry gives one.
University of California at San Francisco ( Site 1008)
San Francisco, California
Yale-New Haven Hospital-Yale Cancer Center ( Site 1011)
New Haven, Connecticut
University of Chicago ( Site 1013)
Chicago, Illinois
University of Iowa ( Site 1012)
Iowa City, Iowa
Henry Ford Health System ( Site 1014)
Detroit, Michigan
Laura and Isaac Perlmutter Cancer Center ( Site 1016)
New York, New York
Memorial Sloan Kettering Cancer Center ( Site 1002)
New York, New York
Duke Cancer Institute ( Site 1015)
Durham, North Carolina
UPMC Cancer Center/Hillman Cancer Center ( Site 1017)
Pittsburgh, Pennsylvania
UTSW Medical Center ( Site 1003)
Dallas, Texas
Blacktown Hospital ( Site 1601)
Blacktown, New South Wales, Australia
St George Hospital ( Site 1602)
Kogarah, New South Wales, Australia
Royal Brisbane and Women's Hospital ( Site 1603)
Herston, Queensland, Australia
Austin Health ( Site 1600)
Heidelberg, Victoria, Australia
Princess Margaret Cancer Centre ( Site 1101)
Toronto, Ontario, Canada
Jewish General Hospital ( Site 1100)
Montreal, Quebec, Canada
James Lind Centro de Investigacion del Cancer ( Site 2108)
Temuco, Araucania, Chile
CIDO SpA-Oncology ( Site 2106)
Temuco, Araucania, Chile
FALP-UIDO ( Site 2100)
Santiago, Region M. de Santiago, Chile
Oncovida ( Site 2107)
Santiago, Region M. de Santiago, Chile
Bradfordhill-Clinical Area ( Site 2101)
Santiago, Region M. de Santiago, Chile
ONCOCENTRO APYS-ACEREY ( Site 2103)
Viña del Mar, Valparaiso, Chile
Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia-Center Investigator ( Site 1900)
Bogotá, Bogota D.C., Colombia
Sociedad De Oncologia Y Hematologia Del Cesar-Oncology ( Site 1905)
Valledupar, Cesar Department, Colombia
Instituto Médico de Alta Tecnologia S.A.S ( Site 1904)
Montería, Departamento de Córdoba, Colombia
Fundación Valle del Lili ( Site 1901)
Cali, Valle del Cauca Department, Colombia
Institut De Cancerologie De Lorraine ( Site 1204)
Vandœuvre-lès-Nancy, Ain, France
C.H.U. de Strasbourg Hopital de Hautepierre ( Site 1203)
Strasbourg, Bas-Rhin, France
Institut Claudius Regaud ( Site 1200)
Toulouse, Haute-Garonne, France
Gustave Roussy ( Site 1202)
Villejuif, Île-de-France Region, France
Országos Onkológiai Intézet-Urogenitális Tumorok és Klinikai Farmakológiai Osztály ( Site 2301)
Budapest, Pest County, Hungary
Rambam MC ( Site 1500)
Haifa, Israel
Hadassah Medical Center-Oncology ( Site 1504)
Jerusalem, Israel
Rabin Medical Center ( Site 1502)
Petah Tikva, Israel
Sheba Medical Center - Oncology Division ( Site 1501)
Ramat Gan, Israel
Sourasky Medical Center ( Site 1503)
Tel Aviv, Israel
Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL)-medical oncology ( Site 2402)
Amsterdam, North Holland, Netherlands
Erasmus Medisch Centrum ( Site 2401)
Rotterdam, South Holland, Netherlands
Auckland City Hospital ( Site 1700)
Auckland, New Zealand
Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 2201)
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
Showing 40 of 55 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.